Tesamorelin and ipamorelin both increase growth hormone, but they sit at very different points on the evidence and regulatory map. Tesamorelin is an FDA-approved GHRH analog with human trial data; ipamorelin is a research-only secretagogue that works through a different receptor. This comparison keeps to sourced, factual dimensions.
Reviewed for accuracy · Last reviewed July 7, 2026On regulatory footing the two are not comparable. Tesamorelin has an approved label (Egrifta), a defined daily dose, and Phase 3 evidence for reducing visceral fat in HIV-associated lipodystrophy. Ipamorelin has no approval and rests mainly on preclinical work plus a human trial that missed its primary endpoint.
Mechanistically they raise growth hormone by different routes: tesamorelin through the pituitary GHRH receptor, ipamorelin through the ghrelin receptor. Neither is approved for the body-composition or anti-aging uses they are often discussed for, and tesamorelin's own approval is specific to the HIV setting rather than general fat loss.
For anyone comparing them for off-label goals, the honest framing is that tesamorelin has real human data in a narrow indication while ipamorelin has thin human evidence in any indication. That is a difference in how much is known, not a ranking of effectiveness, and the choice is a medical one.
This page is an independent educational reference and is not medical advice. Talk to a doctor before starting any compound.